Skip to main content Skip to article
 
to view subscribed content from home
 
Volume 395, Issue 10240, 13–19 June 2020, Pages 1845-1854

Articles
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Summary

Background

A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain.

Methods

We did a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine in Wuhan, China. Healthy adults aged between 18 and 60 years were sequentially enrolled and allocated to one of three dose groups (5 × 1010, 1 × 1011, and 1·5 × 1011 viral particles) to receive an intramuscular injection of vaccine. The primary outcome was adverse events in the 7 days post-vaccination. Safety was assessed over 28 days post-vaccination. Specific antibodies were measured with ELISA, and the neutralising antibody responses induced by vaccination were detected with SARS-CoV-2 virus neutralisation and pseudovirus neutralisation tests. T-cell responses were assessed by enzyme-linked immunospot and flow-cytometry assays. This study is registered with , .

Findings

kok体育官方网站Between March 16 and March 27, 2020, we screened 195 individuals for eligibility. Of them, 108 participants (51% male, 49% female; mean age 36·3 years) were recruited and received the low dose (n=36), middle dose (n=36), or high dose (n=36) of the vaccine. All enrolled participants were included in the analysis. At least one adverse reaction within the first 7 days after the vaccination was reported in 30 (83%) participants in the low dose group, 30 (83%) participants in the middle dose group, and 27 (75%) participants in the high dose group. The most common injection site adverse reaction was pain, which was reported in 58 (54%) vaccine recipients, and the most commonly reported systematic adverse reactions were fever (50 [46%]), fatigue (47 [44%]), headache (42 [39%]), and muscle pain (18 [17%]. Most adverse reactions that were reported in all dose groups were mild or moderate in severity. No serious adverse event was noted within 28 days post-vaccination. ELISA antibodies and neutralising antibodies increased significantly at day 14, and peaked 28 days post-vaccination. Specific T-cell response peaked at day 14 post-vaccination.

Interpretation

kok体育官方网站The Ad5 vectored COVID-19 vaccine is tolerable and immunogenic at 28 days post-vaccination. Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy adults, and rapid specific T-cell responses were noted from day 14 post-vaccination. Our findings suggest that the Ad5 vectored COVID-19 vaccine warrants further investigation.

Funding

kok体育官方网站National Key R&D Program of China, National Science and Technology Major Project, and CanSino Biologics.

Contributed equally

View Abstract
<",c,' onload="var d=',n,";d.getElementsByTagName('head')[0].",d,"(d.",g,"('script')).",i,"='",a.l,"'\">"].join("")}var c="body",e=h[c];if(!e)return setTimeout(q,100);a.P(1);var d="appendChild",g="createElement",i="src",k=h[g]("div"),l=k[d](h[g]("div")),f=h[g]("iframe"),n="document",p;k.style.display="none";e.insertBefore(k,e.firstChild).id=o+"-"+j;f.frameBorder="0";f.id=o+"-frame-"+j;/MSIE[ ]+6/.test(navigator.userAgent)&&(f[i]="javascript:false");f.allowTransparency="true";l[d](f);try{f.contentWindow[n].open()}catch(s){a.domain=h.domain,p="javascript:var d="+n+".open();d.domain='"+h.domain+"';",f[i]=p+"void(0);"}try{var r=f.contentWindow[n];r.write(b());r.close()}catch(t){f[i]=p+'d.write("'+b().replace(/"/g,String.fromCharCode(92)+'"')+'");d.close();'}a.P(2)};a.l&&setTimeout(q,0)})()}();c[b].lv="1";return c[b]}var o="lightningjs",k=window[o]=g(o);k.require=g;k.modules=c}({}); window.usabilla_live = lightningjs.require("usabilla_live", "http://w.usabilla.com/eb1c14a91932.js"); var customData = {}; if(window.pageData && pageData.content && pageData.content[0]) { customData.entitlementType = pageData.content[0].entitlementType; } if(window.pageData && pageData.visitor) { customData.accessType = pageData.visitor.accessType; customData.accountId = pageData.visitor.accountId; customData.loginStatus = pageData.visitor.loginStatus; } usabilla_live("data", {"custom": customData });